This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
jak1-2
JAK1/2
Janus kinase 1 and 2; non-receptor tyrosine kinases that phosphorylate STAT proteins downstream of cytokine receptors (IL-6, IFN-gamma, EPO, GM-CSF). JAK2 V617F drives myeloproliferative neoplasms. Inhibited by ruxolitinib (MF/PV), baricitinib (RA), and upadacitinib.
Entry Metadata
| Field | Value |
|---|---|
| ID | jak1-2 |
| Name | JAK1/2 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2005;2005:195-200. · PubMed 16304378
- Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. · PubMed 22375971
- Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis. Lancet. 2017;390(10093):457-468. · PubMed 28629651